Stearoyl-CoA desaturase 1 inhibition induces ER stress-mediated apoptosis in ovarian cancer cells
Juwon Lee, Suin Jang, Jihye Im, Youngjin Han, Soochi Kim, HyunA Jo, Wenyu Wang, Untack Cho, Se Ik Kim, Aeran Seol, Boyun Kim & Yong Sang Song
Research | Published: 02 April 2024
Sialyl-Tn serves as a potential therapeutic target for ovarian cancer
Linah Al-Alem, Jillian M. Prendergast, Justin Clark, Bianca Zarrella, Dominique T. Zarrella, Sarah J. Hill, Whitfield B. Growdon, Venkatesh Pooladanda, David R. Spriggs, Daniel Cramer, Kevin M. Elias, Rawan I. Nazer, Steven J. Skates, Jeff Behrens, Daniel T. Dransfield & Bo R. Rueda
Research | Published: 02 April 2024
PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials
István Baradács, Brigitta Teutsch, Alex Váradi, Alexandra Bilá, Ádám Vincze, Péter Hegyi, Tamás Fazekas, Balázs Komoróczy, Péter Nyirády, Nándor Ács, Ferenc Bánhidy & Balázs Lintner
Review | Published: 26 February 2024
From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer
Zesi Liu, Chunli Jing & Fandou Kong
Review | Published: 12 February 2024
The regulation of plasma gelsolin by DNA methylation in ovarian cancer chemo-resistance
Hafiza Bushra Manzoor, Meshach Asare-Werehene, Satyajit Dey Pereira, Kapaettu Satyamoorthy & Benjamin K. Tsang
Research | Published: 12 January 2024
A Novel pyroptosis-related signature for predicting prognosis and evaluating tumor immune microenvironment in ovarian cancer
Jiani Yang, Chao Wang, Yue Zhang, Shanshan Cheng, Yanna Xu & Yu Wang
Research | Published: 20 September 2023
A methylation- and immune-related lncRNA signature to predict ovarian cancer outcome and uncover mechanisms of chemoresistance
Lu Chen, Wujiang Gao, Li Lin, Chunli Sha, Taoqiong Li, Qi Chen, Hong Wei, Meiling Yang, Jie Xing, Mengxue Zhang, Shijie Zhao, Wenlin Xu, Yuefeng Li, Lulu Long & Xiaolan Zhu
Research | Published: 06 September 2023
The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial
Youwen Zhu, Kun Liu, Hui Cao & Hong Zhu
Research | Published: 21 August 2023
Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer
A. W. Adamson, Y. C. Ding, L. Steele, L. A. Leong, R. Morgan, M. T. Wakabayashi, E. S. Han, T. H. Dellinger, P. S. Lin, A. A. Hakim, S. Wilczynski, C. D. Warden, S. Tao, V. Bedell, M. C. Cristea & S. L. Neuhausen
Research | Published: 17 July 2023
Trends in incidence and mortality for ovarian cancer in China from 1990 to 2019 and its forecasted levels in 30 years
Jianyang Feng, Lijiang Xu, Yangping Chen, Rongjin Lin, Haoxian Li & Hong He
Research | Published: 14 July 2023
LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer
Goutam Dey, Rashmi Bharti, Chad Braley, Ravi Alluri, Emily Esakov, Katie Crean-Tate, Keith McCrae, Amy Joehlin-Price, Peter G. Rose, Justin Lathia, Zihua Gong & Ofer Reizes
Research | Published: 27 June 2023
SPON1 is an independent prognostic biomarker for ovarian cancer
Ryoya Miyakawa, Makoto Kobayashi, Kotaro Sugimoto, Yuta Endo, Manabu Kojima, Yasuyuki Kobayashi, Shigenori Furukawa, Tsuyoshi Honda, Takafumi Watanabe, Shigeyuki Asano, Shu Soeda, Yuko Hashimoto, Keiya Fujimori & Hideki Chiba
Research | Published: 13 May 2023
